Indications

The Company’s products are targeted to treat adult patients.
Protocols are being developed for patients with the following indications:

  • Hematological Malignancy:
    1. Chronic Lymphocytic Leukemia
    2. Non-Hodgkins Lymphoma
    3. Multiple Myeloma
  • Prostate Cancer (primary and metastatic)
  • Breast Cancer (primary and metastatic)
  • Glioblastoma Multiforme brain tumor
  • Colorectal Cancer with liver metastases
  • Kidney Cancer
  • Non-Small Cell Lung Cancer